{"type":"trials","record":{"id":36363,"source_id":"clinicaltrials-gov","external_id":"NCT04238494","title":"Muscle Multi-parametric NMR Imaging Development in Aged People With Sarcopenia or Frailty Syndrome; CLINical Study","brief_summary":"Frailty is a multideterminant syndrome in which muscle function appears to play a central role. Muscle function depends on brain control, nutrition and perfusion. We hypothesized that multiparametric MRI assessment combined with comprehensive gerontological assessment (CGA) and routine biological assessment of inflammation in a sample of older people with and without diabetes will allow to explore on one side the possibilities of multi-parametric MRI muscle and brain imaging to describe the correlates of frailty and on the other side will describe the different muscle/brain alterations due to diabetes in frailty. The main objective is to compare the lipid percent of the rectus femoris in frail and pre-frail older subjects and in non-frail older subjects.","overall_status":"Unknown","phases":[],"study_type":"INTERVENTIONAL","sponsor":"University Hospital, Bordeaux","enrollment":60,"countries":["France"],"start_date":"2019-10-18","completion_date":"2022-05-30","last_update_date":"2021-10-20","source_url":"https://clinicaltrials.gov/study/NCT04238494","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Unknown. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:20:24.196666+00:00","last_seen_at":"2026-09-25T06:15:20.281+00:00","metadata":{"sex":"ALL","acronym":"MIDAS","age_range":"70 Years to 90 Years","comparator":null,"organization":"University Hospital, Bordeaux","interventions":["Nuclear magnetic resonance (NMR)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Fat involution and trophicity in rectus femoris — day 1","description of brain by MRI — day 1","Evaluation of inflammation grade — day 1","measure the myostatin rate — day 1","measure the cystatin-C and creatinine rate — day 1","measure the serum interleukin IL-1b and IL-18 rate — day 1"],"design_description":"NON RANDOMIZED · PARALLEL · OTHER · NONE","source_has_results":false},"controlled_terms":["Frail Elderly Syndrome","Diabetes","Nuclear magnetic resonance (NMR)"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: sarcopenia.","quality_checked_at":"2026-09-25T06:15:30.843286+00:00","duplicate_cluster_key":"id:nct04238494","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2019-10-18 to 2022-05-30","comparator":null,"confidence":"structured-source","population":"ALL · 70 Years to 90 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:15:20.379Z","intervention":["Nuclear magnetic resonance (NMR)"],"participants":60,"study_design":"NON RANDOMIZED · PARALLEL · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Fat involution and trophicity in rectus femoris — day 1","description of brain by MRI — day 1","Evaluation of inflammation grade — day 1","measure the myostatin rate — day 1","measure the cystatin-C and creatinine rate — day 1","measure the serum interleukin IL-1b and IL-18 rate — day 1"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"sarcopenia","is_published":true,"match_reasons":["Title contains controlled term: sarcopenia.","Title supplies longevity context: aging, frailty.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Sarcopenia","slug":"sarcopenia"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/36363","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}